Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth (2009)
Sequence: ac-GALFLGFLGAAGSTMGAWSQPKKKRKV-Cya
| Experiment Id | EXP000164 |
|---|---|
| Paper | Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth |
| Peptide | MPGNLS (parent MPG) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | 0.25–200 nM (dose–response reported) |
| Mixing Ratio | 20:1 peptide:siRNA |
| Formulation Format | Non-covalent MPGNLS/siRNA nanoparticles |
| Formulation Components | 260 ± 50 nm (at 20:1) |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HeLa, HS68 |
| Animal Model | |
| Administration Route | |
| Output Type | gene knockdown |
| Output Value | |
| Output Units | |
| Output Notes | Lower potency than MPG-8 (IC50 tens of nM) |
| Toxicity Notes | |
| Curation Notes |